JP2584636B2 - Gastritis treatment - Google Patents
Gastritis treatmentInfo
- Publication number
- JP2584636B2 JP2584636B2 JP62222098A JP22209887A JP2584636B2 JP 2584636 B2 JP2584636 B2 JP 2584636B2 JP 62222098 A JP62222098 A JP 62222098A JP 22209887 A JP22209887 A JP 22209887A JP 2584636 B2 JP2584636 B2 JP 2584636B2
- Authority
- JP
- Japan
- Prior art keywords
- gastritis
- improvement
- treatment
- none
- side effects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Description
【発明の詳細な説明】 産業上の利用分野 本発明は、胃炎治療剤に関するものである。Description: TECHNICAL FIELD The present invention relates to a therapeutic agent for gastritis.
従来の技術 FM−100は甘草のメタノール抽出液にアルカリを加え
た後、酸により分別沈澱を行うことにより得られる抗潰
瘍成分である（特公昭41−15712、特公昭46−13035、応
用薬理（1981）Vol22（４）P581−585参照）。このFM−
100はすでに抗潰瘍剤「アスパロン 」として市販され
ている。Conventional technology FM-100 adds alkali to methanol extract of licorice.
And then the anti-crush obtained by fractional precipitation with acid.
It is an ulcer component (Japanese Patent Publication No. 41-15712, Japanese Patent Publication No. 46-13035,
Pharmacology (1981) Vol 22 (4) P581-585). This FM-
100 are already anti-ulcer agents Marketed as
ing.
発明が解決しようとする問題点 現在胃炎に対して種々の薬剤が使用されているが、一
長一短であり、胃炎に対し、有効かつ副作用のない薬剤
が求められている。Problems to be Solved by the Invention At present, various drugs are used for gastritis, but there are demands for drugs that have advantages and disadvantages and that are effective and have no side effects for gastritis.
問題点を解決するための手段 本発明者は上記目的を達成するため種々検討の結果、
FM−100は胃炎治療に優れた効果を有するとともに副作
用も少ないことを見い出し本発明を完成したものであ
る。Means for Solving the Problems The present inventor has conducted various studies in order to achieve the above object,
It has been found that FM-100 has an excellent effect in treating gastritis and has few side effects, and has completed the present invention.
即ち、本発明はFM−100を有効成分とする胃炎治療剤
に関するものである。That is, the present invention relates to a therapeutic agent for gastritis containing FM-100 as an active ingredient.
FM−100は常法により補助剤とともに、医薬として用
いられる担体と混合して、カプセル、散剤、細粒剤、顆
粒剤、錠剤、液剤、懸濁剤、乳剤、ドライシロップとす
ることができる。これらの場合の医薬用担体としては、
例えば、乳糖、デンプン、結晶セルロース、ステアリン
酸マグネシウム、Ｄ−マンニトール、ヒドロキシプロピ
ルセルロース、デキストリン、白糖、カオリン、炭酸カ
ルシウム、タルク、シヨ糖脂肪酸エステル、カルボキシ
メチルセルロースカルシウム、カルボキシメチルセルロ
ースナトリウム、中鎖脂肪酸トリグリセライド等が好ま
しい。FM-100 can be mixed with auxiliaries and carriers used as pharmaceuticals in the usual manner to give capsules, powders, fine granules, granules, tablets, solutions, suspensions, emulsions and dry syrups. As a pharmaceutical carrier in these cases,
For example, lactose, starch, crystalline cellulose, magnesium stearate, D-mannitol, hydroxypropyl cellulose, dextrin, sucrose, kaolin, calcium carbonate, talc, sucrose fatty acid ester, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, medium chain fatty acid triglyceride, etc. Is preferred.
FM−100の投与量は年齢、個人差、病状などにより異
なり一概には言えないが、一般に経口で１日量として成
人で200mg〜3000mg好ましくは500mg〜2000mgである。通
常１日３回〜４回に分けて経口投与する。The dosage of FM-100 varies depending on age, individual differences, medical conditions and the like, and cannot be unconditionally determined. However, it is generally 200 mg to 3000 mg, preferably 500 mg to 2000 mg as a daily oral dose for an adult. Oral administration is usually divided into three to four times a day.
FM−100はすでにアスパロン として胃潰瘍治療に用
いられており、安全性は確認されている。例えばマウス
での経口での急性毒性（LD50）は800mg/Kg以上で、非常
に安全性の高いものである。 FM-100 is already Aspalon As for gastric ulcer treatment
Safety has been confirmed. Mouse for example
Acute oral toxicity (LD50) Is over 800mg / Kg, very
It is highly secure.
作用効果 FM−100の優れた胃炎治療効果を試験により示す。Action and effect The excellent gastritis treatment effect of FM-100 is shown by the test.
試験例 （１）製 剤:FM−100を200mg含む製剤例１のカプセ
ル。Test Example (1) Formulation: The capsule of Formulation Example 1 containing 200 mg of FM-100.
（２）試験方法：上記のカプセルを、胃炎成人患者（急
性胃炎70名、慢性胃炎52名、その他10名）に１回２カプ
セル１日４回（毎食後および就寝前）服用させ、原則４
週間投与する。但し投薬期間中に内視鏡により治癒を確
認した場合は、その時点で投薬を中止した。(2) Test method: The above capsules were taken by adult patients with gastritis (70 patients with acute gastritis, 52 with chronic gastritis, and 10 others) at a time, 2 capsules 4 times a day (after every meal and before bedtime).
Administer for a week. However, if healing was confirmed by an endoscope during the dosing period, the dosing was stopped at that time.
（３）評価方法及び評価結果 ａ）内視鏡検査 治療前、１週、２週及び４週後に、各時期の内視鏡所
見の出血、びらん、発赤、浮腫、更に胃全体について、
それぞれ治療前と比較し、各病変毎に治癒過程の推移を
考慮し、「著明改善」、「中等度改善」、「軽度改
善」、「不変」、「悪化」及び試験期間中に病変のみら
れなかつた「なし→なし」の６段階で評価した。さらに
各病変を総合した胃全体の内視鏡総合改善度を「なし→
なし」を除く５段階で判定した。その結果を表１及び表
２に示す。なお ｂ）自・他覚症状検査 投与前、３日、１週、２週、４週後に実施し、嘔気、
嘔吐、食欲不振、心窩部痛、腹部膨満感、胸やけ、吐血
及び下血について観察し、それぞれの自・他覚症状につ
いて、その程度と消失課程を考慮し「著明改善」、「中
等度改善」、「軽度改善」、「不変」、「悪化」及び
「なし→なし」の６段階で判定し、各症状の判定を総合
して自・他覚症状総合改善度を、「なし→なし」を除く
５段階で評価した。その結果を表３に示す。(3) Evaluation method and evaluation results a) Endoscopy Before, 1 week, 2 weeks, and 4 weeks after treatment, bleeding, erosion, redness, edema, and the entire stomach of the endoscopic findings at each time period,
Considering the progress of the healing process for each lesion compared to before treatment, "significant improvement", "moderate improvement", "mild improvement", "unchanged", "worse" and only the lesion during the test period The evaluation was made on a 6-point scale of “None → None”. In addition, the overall improvement of the endoscope of the entire stomach, which combines each lesion
The evaluation was made in five steps except for "none". The results are shown in Tables 1 and 2. Note that b) Inspection of self-objective symptoms Before, 3 days, 1 week, 2 weeks, 4 weeks after administration, nausea,
Observe vomiting, anorexia, epigastric pain, abdominal bloating, heartburn, vomiting blood and melena, and for each self-objective symptom, take into account the degree and disappearance course. Judgment is made in six stages of “improvement”, “mild improvement”, “unchanged”, “deterioration”, and “none → none”. The evaluation was made in five steps excluding "." Table 3 shows the results.
ｃ）全般改善度 全般改善度は内視鏡及び自・他覚症状総合改善度を総
合して「著明改善」、「中等度改善」、「軽度改善」、
「不変」、及び「悪化」の５段階で判定した。その結果
を表４に示す。 c) Degree of general improvement The degree of general improvement is defined as "significant improvement", "moderate improvement", "mild improvement",
Judgment was made in five stages of “unchanged” and “deteriorated”. Table 4 shows the results.
ｄ）副作用 発現した症状の種類、時期、程度について観察した。
その結果、132例中皮膚掻痒感及び発疹１例（中程度、
発現日４日目）、皮疹１例（中程度、発現日23日目）、
下痢１例（中程度、発現日１日目）の計３例に副作用が
認められたのみであつた。 d) Side effects The types, timing and extent of the symptoms that occurred were observed.
As a result, skin pruritus and rash in 132 cases (medium,
Onset day 4), rash 1 case (medium, onset day 23),
Side effects were observed only in a total of three cases of diarrhea in one case (medium, on the first day of onset).
以上から明らかなように、本発明の胃炎治療剤の胃炎
治療に非常に有用であり、かつ副作用も少ないのであ
る。As is clear from the above, the therapeutic agent for gastritis of the present invention is very useful for gastritis treatment and has few side effects.
次に本発明の製剤例を示す。 Next, Formulation Examples of the present invention are shown.
製剤例１ （カプセル） FM−100 200mg 賦形剤（バレイシヨデンプン） 15mg 崩壊剤（低置換度ヒドロキシプロピルセルロース）30mg 滑沢剤（ステアリン酸マグネシウム） 5mg を着色硬カプセルに充填し、カプセル剤とする。Formulation Example 1 (Capsule) FM-100 200mg Excipient (valley starch) 15mg Disintegrant (low-substituted hydroxypropylcellulose) 30mg Lubricant (magnesium stearate) 5mg is filled in a colored hard capsule, I do.
製剤例２ （細粒） FM−100 40部 賦形剤（乳糖） 17部 崩壊剤（低置換度ヒドロキシプロピルセルロース）35部 崩壊補助剤（シヨ糖脂肪酸エステル） ５部 結合剤（ヒドロキシプロピルセルロース） ３部 を混合練合、破砕造粒後、乾燥、整粒することにより、
細粒剤を得た。Formulation Example 2 (Fine granules) FM-100 40 parts Excipient (lactose) 17 parts Disintegrant (low-substituted hydroxypropylcellulose) 35 parts Disintegration aid (sucrose fatty acid ester) 5 parts Binder (hydroxypropylcellulose) After mixing and kneading 3 parts, crushing and granulating, drying and sizing,
A fine granule was obtained.
───────────────────────────────────────────────────── フロントページの続き (56)参考文献 特公 昭46−13035（ＪＰ，Ｂ１) 薬局、Ｖｏｌ．35，Ｎｏ．11，第23− 27頁（1984) 薬局、Ｖｏｌ．35，Ｎｏ．11，第55− 60頁（1984) 薬局、Ｖｏｌ．29，Ｎｏ．９，第25− 29頁（1978) ──────────────────────────────────────────────────続 き Continued on front page (56) References JP-B-46-13035 (JP, B1) Pharmacy, Vol. 35, No. 11, pages 23-27 (1984) Pharmacy, Vol. 35, No. 11, pages 55-60 (1984) Pharmacies, Vol. 29, No. 9, pages 25-29 (1978)
Claims (1)
る胃炎治療剤1. A therapeutic agent for gastritis, comprising FM-100 as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62222098A JP2584636B2 (en) | 1987-09-07 | 1987-09-07 | Gastritis treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62222098A JP2584636B2 (en) | 1987-09-07 | 1987-09-07 | Gastritis treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6466125A JPS6466125A (en) | 1989-03-13 |
| JP2584636B2 true JP2584636B2 (en) | 1997-02-26 |
Family
ID=16777104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62222098A Expired - Fee Related JP2584636B2 (en) | 1987-09-07 | 1987-09-07 | Gastritis treatment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2584636B2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8525931B2 (en) | 2002-01-11 | 2013-09-03 | Thomson Licensing | Method and apparatus for isolating IIC bus noise from a tuner in a television receiver |
| JP2005255662A (en) * | 2004-05-11 | 2005-09-22 | Kokuhi Tei | Plant component mixture for beverage extraction, mixed liquor of plant component and plant component mixture |
| WO2010070672A2 (en) * | 2008-11-26 | 2010-06-24 | Amit Agarwal | A phytochemical composition and a process thereof |
| CN103585331B (en) * | 2013-10-28 | 2015-10-28 | 泰安市岱岳区山农高科兽药研究所 | A kind of Chinese medicine preparation preventing and treating poultry proventriculitis, ventriculitis |
| CN104587183A (en) * | 2014-12-26 | 2015-05-06 | 武海波 | traditional Chinese medicine composition for treating dyspepsia |
-
1987
- 1987-09-07 JP JP62222098A patent/JP2584636B2/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| 薬局、Ｖｏｌ．２９，Ｎｏ．９，第２５−２９頁（１９７８） |
| 薬局、Ｖｏｌ．３５，Ｎｏ．１１，第２３−２７頁（１９８４） |
| 薬局、Ｖｏｌ．３５，Ｎｏ．１１，第５５−６０頁（１９８４） |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6466125A (en) | 1989-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1991000096A1 (en) | Low-dosage sublingual aspirin | |
| AT401468B (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING RANITIDE INISMUTCITRATE | |
| KR100202154B1 (en) | Film coated tablet of paracetamol and domperidone | |
| JPH05186332A (en) | Method for preparing pharmaceutical product provided with at least two different kinds of active substances and use thereof | |
| JPS62501845A (en) | controlled release potassium chloride | |
| Berry et al. | Indomethacin and naproxen suppositories in the treatment of rheumatoid arthritis. | |
| EP0629400B1 (en) | Idebenone compositions for treating Alzheimer's disease | |
| JPH1036269A (en) | Drug for reducing dysmenorrhoe and/or syndrome before menstruation | |
| JP2584636B2 (en) | Gastritis treatment | |
| JP2704721B2 (en) | Ibuprofen formulation | |
| JPS5938203B2 (en) | A therapeutic agent for cerebral circulation disorders whose main ingredient is coenzyme Q. | |
| JPH0140009B2 (en) | ||
| DE3517820A1 (en) | PHARMACEUTICAL PREPARATIONS WITH ANTI-HYPERTENSIVE AND CARDIOPROTECTIVE EFFECT | |
| RU2333764C1 (en) | Medicine for treatment and prevention of thyroid gland diseases | |
| JP3982889B2 (en) | Pharmaceutical preparations containing ibuprofen | |
| KR20000022204A (en) | Preventives/remedies for stomatitis | |
| GB2197198A (en) | Analgesic preparations | |
| JP2000344665A (en) | Analgesic | |
| RU2101014C1 (en) | Analgetic, antiinflammatory, antipyretic medicinal agent and a method of its preparing | |
| JP2000229853A (en) | Menstruation pain-improving composition | |
| EP1075257A1 (en) | Use of triclosan for the treatment of helicobacter pylori infections | |
| RU2751351C2 (en) | Oral ibuprofen medication | |
| JPS5852220A (en) | Lowering agent for uric acid value in blood serum | |
| JPH10509729A (en) | Kit for osteoporosis treatment cycle | |
| JPH0143725B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |